NCT02160132.

Methods	Parallel RCT
Participants	Setting: multicentre Country: China Patients with age 14 to 65 years, regardless of gender; clinical evaluation and renal biopsy diagnostic for IgAN, presenting with active pathological changes,including cellular crescents,necrosis and microthrombus; average urinary protein excretion of 0.5 to 3.5 g/24 hours on two successive examinations; eGFR ≥ 50 mL/min/1.73 m2 Number: 180 participants planned Mean age ± SD (years): not available Sex (M/F): not available Exclusion criteria: Secondary IgAN such as SLE, HSP; nephritis and hepatitis B ‐associated nephritis; rapidly progressive nephritic syndrome (crescent formation ≥ 50%); AKI, including rapidly progressive IgAN; current or recent (within 30 days) exposure to high‐dose of steroids or immunosuppressive therapy (CPA, MMF, CSA, FK506); date of renal biopsy exceeds more than 30 days; cirrhosis, chronic active liver disease; history of significant gastrointestinal disorders (e.g. severe chronic diarrhoea or active peptic ulcer disease); any active systemic infection or history of serious infection within one month; other major organ system disease (e.g. serious cardiovascular diseases including congestive heart failure, chronic obstructive pulmonary disease, asthma requiring oral steroid treatment or central nervous system diseases); active tuberculosis; malignant hypertension that is difficult to be controlled by oral drugs; known allergy, contraindication or intolerance to the steroids; pregnancy or breast feeding at the time of entry or unwillingness to comply with measures for contraception; malignant tumours; excessive drinking or drug abuse; mental aberrations; current or recent (within 30 days) exposure to any other investigational drugs
Interventions	Treatment group 1 IV methylprednisolone 0.5 g/day for 3 consecutive days in the 1st, 2nd and 3rd month, and then oral methylprednisolone 0.4 mg/kg/day on consecutive days for 6 months Treatment group 2 IV Methylprednisolone 0.5 g/day for 3 consecutive days in the 1st, 3rd and 5th month, and then oral methylprednisolone 0.4 mg/kg/day on consecutive days for 6 months
Outcomes	Remission of proteinuria (complete or partial) Deterioration of kidney function Longitudinal decline of kidney function (eGFR)
Notes	Study completed on December 2016 Emailed investigators on 21.5.2018 to request update on trial status, but not answer was provided Clinicaltrials.gov identifier: NCT02160132 No study results available